# Clene Inc.

Type: Company (CLNN)

Source: GetYourBrief — https://getyourbrief.com/entity/clene-inc
Canonical HTML page: https://getyourbrief.com/entity/clene-inc

## Timeline

- **2026-08-14**: Q2 2026 financial results reported — Laser Photonics reports net sales of $1.8 million and positive gross margin; Zeo reports 23% sequential revenue growth; Clene reports Q2 results and CNM-Au8 program updates.
- **2026-06-30**: Q2 2026 reporting period ends — Laser Photonics, Zeo Energy, and Clene complete the second quarter ended June 30, 2026.
- **2026-05**: FDA meeting minutes confirm accelerated approval pathway for CNM-Au8 — Clene receives formal meeting minutes stating its proposed NfL data may be capable of supporting an NDA for CNM-Au8 in ALS under accelerated approval.

## Recent coverage (3 stories, network-wide)

### Laser Photonics Q2 Sales Jump 97% to $1.8M; Gross Margin Turns Positive
2026-08-15 01:53:43 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Laser Photonics reports Q2 net sales of $1.8M, up 97% sequentially, with gross margin improving to 8.4% from negative 42.4%. The company's anti-drone Laser Shield system is advancing through U.S. defense evaluations, while Zeo and Clene also posted Q2 updates in the same reporting window.
Full story: https://getfinancebrief.com/story/laser-photonics-q2-2026-earnings

### Zeo Energy Q2 Revenue Rises 23% Sequentially as Solar Permits Fall 40%
2026-08-15 01:53:34 · Sector: climate · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Zeo Energy reports Q2 revenue up 23% sequentially and 9% year over year despite a 40% industry-wide drop in residential solar permits. The company credits tax equity fund closures and a commercial energy storage strategy targeting data center partners. Management sees the improvement as an inflection entering a new growth cycle.
Full story: https://getclimatebrief.com/story/zeo-energy-q2-2026-solar-revenue-market

### Clene's CNM-Au8 ALS NDA Path Advances with Survival Data from 2 Phase 2 Trials
2026-08-15 01:53:22 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Clene Inc. reports FDA meeting minutes confirm an accelerated approval pathway for CNM-Au8 in ALS. New biomarker analyses link NfL stabilization to longer survival and improved function. The company plans to submit an NDA, citing data from two completed Phase 2 trials.
Full story: https://getbiobrief.com/story/clene-cnm-au8-als-nda-q2-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.